Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Deals

Ningbo HicRen Biotech Completes RMB100M Pre-Series C Financing for Orthopedic Robots

Fineline Cube Jul 15, 2022

Ningbo HicRen Biotechnology Co., Ltd, a China-based robotics-driven minimally invasive orthopedics platform, announced the completion...

Company Deals

CStone Pharmaceuticals Explores Strategic Options Including Buyout

Fineline Cube Jul 15, 2022

China-based CStone Pharmaceuticals (HKG: 2616) is evaluating strategic options, including a potential buyout, according to...

Drug

BeiGene’s Tislelizumab Faces FDA Delay Due to Inspection Hurdles

Fineline Cube Jul 15, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced a delay in the U.S. FDA’s decision...

Company Deals Drug

Frontier Biotech and Asymchem Partner on COVID-19 Drug FB2001 Development

Fineline Cube Jul 15, 2022

China-based Frontier Biotechnologies Inc. (SHE: 200342) announced a strategic partnership with Asymchem Laboratories (Tianjin) Co.,...

Company Medical Device

Acotec Scientific’s AcoArt Orchid & Dhalia DCB Wins China Approval for AVF PTA

Fineline Cube Jul 14, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that its AcoArt Orchid & Dhalia DCB,...

Company Deals

Orion Holdings to Build Jining Vaccine Plant in China’s Shandong Province

Fineline Cube Jul 14, 2022

South Korea-based conglomerate Orion Holdings Corp. will enter China’s vaccine market by constructing a manufacturing...

Company Drug

Hangzhou DAC Biotech Doses First Patient in DXC007 AML Study

Fineline Cube Jul 14, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing in a...

Company Deals

Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline

Fineline Cube Jul 14, 2022

China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its...

Company Drug

Simcere’s Trilaciclib Wins NMPA Approval for Chemotherapy Myeloprotection

Fineline Cube Jul 14, 2022

Jiangsu Simcere Pharmaceutical Co., Ltd’s trilaciclib has received marketing approval from the National Medical Products...

Policy / Regulatory

China’s 2021 Healthcare Report Shows Rising Life Expectancy, Increased Medical Spending

Fineline Cube Jul 14, 2022

China’s National Health Commission (NHC) released the “Healthcare Statistical Communique 2021,” revealing increased healthcare spending,...

Company Deals

Sinopharm Biotec and Ganzhou Government Partner on Medical Testing and Biotech R&D

Fineline Cube Jul 14, 2022

Sinopharm China National Biotec Group Co., Ltd (CNBG) announced a strategic partnership with the government...

Company Deals

Basecare Medical and Haier Biomedical Partner on IVF Cryopreservation Tech

Fineline Cube Jul 14, 2022

China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) announced a strategic partnership with...

Company Drug

Huadong Medicine’s Biosimilar Victoza (Liraglutide) Accepted for NMPA Review

Fineline Cube Jul 14, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...

Company R&D

CorrectSequence Therapeutics’ tBE Tech Wins USPTO Patent for Gene Editing

Fineline Cube Jul 14, 2022

Shanghai-based gene editing firm CorrectSequence Therapeutics announced it has received a patent from the United...

Company Drug

Zai Lab’s Efgartigimod NDA Accepted by NMPA for Myasthenia Gravis

Fineline Cube Jul 14, 2022

Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that the National Medical Products Administration (NMPA)...

Company Deals

Overland ADCT BioPharma Doses First Patient in Zynlonta’s Phase III LOTIS-5 Study for DLBCL

Fineline Cube Jul 14, 2022

Overland ADCT BioPharma (CY) Ltd, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC...

Company Deals

Triastek Partners with Eli Lilly to Explore 3D Printing for GI Drug Delivery

Fineline Cube Jul 14, 2022

China-based Triastek Inc., a pharmaceutical 3D printing specialist, announced a partnership with US firm Eli...

Company Drug

Zhejiang Medicine’s ARX305 ADC Receives Clinical Trial Approval for CD70-Positive Cancers

Fineline Cube Jul 13, 2022

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that its subsidiary NovoCodex Biopharmaceuticals Ltd has...

Company Deals

GenScript ProBio Partners with ACT Therapeutics on CAR-T Cell Therapy Development

Fineline Cube Jul 13, 2022

GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), announced a memorandum of understanding...

Company Drug

Abbisko Therapeutics’ ABSK021 Receives BTD for Giant Cell Tumor Treatment

Fineline Cube Jul 13, 2022

Shanghai-based Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its Category 1 drug ABSK021 has...

Posts pagination

1 … 695 696 697 … 711

Recent updates

  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
  • Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201
  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
  • NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Company

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.